Algeta appoints senior vp, Protein Therapeutics

New role created to drive development of Thorium platform

Algeta, a Norwegian company focused on the development of novel targeted cancer therapeutics, has appointed Lars Abrahmsen as senior vp, Protein Therapeutics.

Abrahmsen takes responsibility for the development of Oslo-based Algeta’s Thorium platform and for building and overseeing the preclinical development of a pipeline of alpha-pharmaceutical candidates based on tumour-targeted thorium-227 conjugates.

This builds on the progress made with Alpharadin, an alpha-pharmaceutical being developed in a phase III trial by Algeta and Bayer Schering Pharma for treating bone metastases arising from castration-resistant prostate cancer.

Abrahmsen has joined Algeta from Affibody, a Swedish company developing proprietary targeting molecules for therapeutic and diagnostic purposes, where he held the position of chief scientific officer since 2004. Prior to this he worked for Genentech and Pharmacia, where he established their phage display and antibody cloning capabilities.

You may also like

Regulatory

Anticancer agent – radium-223 chloride

Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development

Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227

Norwegian firm to create pipeline of cancer-destroying drugs
Research & Development

Algeta to collaborate with Genzyme

To evaluate Thorium-227 conjugated with a novel tumour-targeting antibody
Research & Development

Algeta signs Alpharadin manufacturing deals

Triggers €5m milestone payment from Bayer Schering Pharma
Research & Development

Scientists develop new technique to fight antimicrobial resistance

The team of researchers from the University of Leicester have developed a new technique to sequence phage genomes from individual plaques and hopes to use it to build fully characterised libraries of bacteriophages, expanding the number of candidates available to tackle drug-resistant infections
Research & Development

Lancet Oncology Commission launches to examine future of academic cancer clinical trials amid funding and regulatory pressures

A global coalition of clinical investigators and patient representatives has launched the Lancet Oncology Commission to address the value and challenges of independent academic cancer clinical trials, amid growing concerns over regulatory complexity, limited public funding and the need for new international collaboration models
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Subscribe now